{
    "id": "dbpedia_6494_1",
    "rank": 2,
    "data": {
        "url": "https://parkinsonsnewstoday.com/author/yedida/",
        "read_more_link": "",
        "language": "en",
        "title": "Yedida Y Bogachkov PhD, Author at Parkinson's News Today",
        "top_image": "https://secure.gravatar.com/avatar/ad8d4f029490faf917df711120b025c1.jpg?d=mp&s=1200",
        "meta_img": "https://secure.gravatar.com/avatar/ad8d4f029490faf917df711120b025c1.jpg?d=mp&s=1200",
        "images": [
            "https://insight.bionewsservices.com/matomo.php?idsite=16&rec=1",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2022/09/PARnewstoday.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-fb.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-ig.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-sc.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-youtube.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2023/08/color-pin.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-fb.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-ig.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-sc.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-youtube.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2023/08/color-pin.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/09/Head-Shot-8.20.21-96x96.jpg",
            "https://bionews.com/global-code/images/linkedin.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/06/BionewsLogo_Black.svg",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-fb.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-ig.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-sc.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-youtube.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2023/08/color-pin.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Yedida Y Bogachkov PhD"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her...",
        "meta_lang": "en",
        "meta_favicon": "https://parkinsonsnewstoday.com/wp-content/uploads/2024/06/cropped-BioNews_Favicon-32x32.png",
        "meta_site_name": "Parkinson's News Today",
        "canonical_link": "https://parkinsonsnewstoday.com/author/yedida/",
        "text": "1st Patient Treated in SHAPE Trial of ATH-1017 for Parkinson’s Dementia\n\nAthira Pharma has dosed the first patient in its Phase 2 clinical trial evaluating ATH-1017 as a treatment for Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) — forms of more severe cognitive impairment in Parkinson’s disease. The trial (NCT04831281), known as SHAPE, is still…\n\nMJFF Supporting Biomarker Test for Early Diagnosis, Patient Monitoring\n\nLundbeck, with support from the Michael J. Fox Foundation (MJFF), is working to develop a “state of the art” biomarker test that could diagnose neurodegenerative diseases like Parkinson’s in early stages. The test, or assay, being developed in collaboration with scientists at the Danish Technical University (DTU) may also…\n\nFirst Patient Treated in Phase 2 Trial of NE3107 for Motor Symptoms\n\nThe first patient has been treated in BioVie’s Phase 2 clinical trial assessing the impact of its investigational therapy, NE3107, on the motor symptoms of Parkinson’s disease. Study results for the Phase 2 trial, known as NM201, are expected by the end of 2022. “Enrollment of the first…\n\nMJFF Awards 2 Bachmann-Strauss Fellowships in Dystonia Research\n\nA new training program, the Bachmann-Strauss Fellowship in Dystonia Research aims to grow the number of researchers focused on the movement disorder known as dystonia. Launched by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the fellowship will support specialized training for those dedicated to investigating the causes…\n\nPhase 2 Trial of Oral Oligomannate Will Target Gut-Brain Axis\n\nGreen Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in people with early-stage Parkinson’s disease, according to a press release. This follows the acceptance of Green Valley‘s investigational new drug (IND) application by the U.S Food and Drug…\n\nSanofi, ABL Bio Join to Develop ABL301 as Potential Treatment\n\nABL Bio and Sanofi are working under a global licensing agreement to jointly develop ABL301 — an investigational bispecific antibody targeting both alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) — in possibly treating Parkinson’s disease. Under the agreement, ABL Bio will lead further preclinical testing and a…\n\n$500,000 Fox Foundation Grant Goes to Yumanity’s YTX-7739 Research\n\nYumanity Therapeutics has been awarded a $500,000 research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help accelerate testing of an investigational Parkinson’s disease therapy, YTX-7739. “MJFF is a globally recognized advocate and supporter of innovative research toward new treatments to stop Parkinson’s…\n\n1st Group Enrolled in Phase 1 Trial of DA01 for Advanced Parkinson’s\n\nBlueRock Therapeutics’ Phase 1 trial testing DA01 — an investigational therapy to restore neuron loss — has completed enrolling its first group of patients with advanced Parkinson’s disease. Meanwhile, enrollment for the second and final high-dose cohort of the open-label trial (NTC04802733) is still ongoing at sites…\n\nMJFF Grant Supports Work Into Potential of Sigma-2 Receptors\n\nCognition Therapeutics has received a grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to support preclinical work into two potential sigma-2 receptor modulators for Parkinson’s disease. The Therapeutic Pipeline Program Grant award, whose amount and duration were not specified, will help to fund studies of these…"
    }
}